About Karus
We are developing innovative medicines for diseases with unmet need. We are investing in our next generation brain-penetrant HDAC6 inhibitors, and our clinical assets are now available for partnering.
Research & Development
Our next generation brain-penetrant HDAC6 inhibitors are not hydroxamic acids. The orally-available small molecules have been developed from our novel stream of in-house chemistry.
Clinical Assets for Partnering
Our two clinical assets have completed Phase I clinical trials at the MD Anderson Cancer Center in Houston, Texas, with encouraging results, and are now available for partnering worldwide.
Created by Instinctif Partners